5α-dihydrotestosterone inhibits 1α,25-dihydroxyvitamin D 3-induced expression of CYP24 in human prostate cancer cells

Prostate

Volumn 63, Issue 3, 2005, Pages 222-230

  Lou, Yan Ru ^a   Nazarova, Nadja ^a   Talonpoika, Riikka ^a   Tuohimaa, Pentti ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

1 ,25 dihydroxyvitamin D3; 25 hydroxyvitamin D3 24 hydroxylase; Androgen receptor; DHT; LNCaP; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CALCIDIOL 24 HYDROXYLASE; CALCITRIOL; HYDROXYFLUTAMIDE; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG; ANILIDE; CYCLOHEXIMIDE; CYTOCHROME P450; DRUG DERIVATIVE; FLUTAMIDE; PROTEIN SYNTHESIS INHIBITOR; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CATABOLISM; CELL FRACTIONATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RADIORECEPTOR ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGENS; ANILIDES; CALCITRIOL; CYCLOHEXIMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROTESTOSTERONE; DRUG INTERACTIONS; FLUTAMIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED;

EID: 17644385896     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20189     Document Type: Article

References (42)

1. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992;52(3):515-520.
2. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139(3):1197-1207.
3. Hsieh T, Wu JM. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 1997;235(3):539-544.
4. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1 alpha,25- Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6(9):727-732.
5. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999;8(3):241-248.
6. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87(3):214-220.
7. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003;164:205-221.
8. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res 1998;47(12):451-475.
9. Chen KS, DeLuca HF. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263(1):1-9.
10. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277(2 Pt 2):F157-F175.
11. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132(5): 1952-1960.
12. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54(3):805-810.
13. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14(3A):1077-1081.
14. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)-retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995;55(23):5621-5627.
15. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1(9):997-1003.
16. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
17. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136(2):796-803.
18. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993;22(1):11-22.
19. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998;273(10):5939-5947.
20. Zhao XY, Ly LH, Peehl DM, Feldman D. 1Alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138(8):3290-3298.
21. Zhao XY, Peehl DM, Navone NM, Feldman D. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000;141(7):2548-2556.
22. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands. Int J Cancer 2000;86(1):40-46.
23. Escaleira MT, Sonohara S, Brentani MM. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 1993;45(4):257-263.
24. Lou YR, Laaksi I, Syvälä H, Bläuer M, Tammela TL, Ylikomi T, Tuohimaa P. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J 2004;18(2):332-334.
25. Tahka KM, Zhuang YH, Tahka S, Tuohimaa P. Photoperiod-induced changes in androgen receptor expression in testes and accessory sex glands of the bank vole, Clethrionomys glareolus. Biol Reprod 1997;56(4):898-908.
26. Turnbull H, Trafford DJ, Makin HL. A rapid and simple method for the measurement of plasma 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 using Sep-Pak C18 cartridges and a single high-performance liquid Chromatographic step. Clin Chim Acta 1982;120(1):65-76.
27. Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies. J Clin Endocrinol Metab 1984;58(1):91-98.
28. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996;28(3):182-194.
29. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140(3):1205-1212.
30. Leman ES, Getzenberg RH. Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells. J Cell Biochem 2003; 88(3):609-622.
31. Ly LH, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999;140(5):2071-2076.
32. Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvala H, Ylikomi T. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer 2004;108(3):367-373.
33. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59(17):4161-4164.
34. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41(3-8):665-669.
35. Berrevoets CA, Veldscholte J, Mulder E. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol 1993;46(6):731-736.
36. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992;267(28):20082-20086.
37. Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher GJ, Voorhees JJ. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 1999; 13(10):1686-1694.
38. Meyer ME, Gronemeyer H, Turcotte B, Bocquel MT, Tasset D, Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 1989;57(3):433-442.
39. Wiren KM, Toombs AR, Zhang XW. Androgen inhibition of MAP kinase pathway and Elk-1 activation in proliferating osteoblasts. J Mol Endocrinol 2004;32(1):209-226.
40. Dwi vedi PP, Hii CS, Ferrante A, Tan J, Der CJ, Omdahl JL, Morris HA, May BK. Role of MAP kinases in the 1,25-dihydroxyvitamin DS-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J Biol Chem 2002;277(33):29643-29653.
41. Armbrecht HJ, Chen ML, Hodam TL, Boltz MA. Induction of 24-hydroxylase cytochrome P450 mRNA by 1,25-dihydroxyvitamin D and phorbol esters in normal rat kidney (NRK-52E) cells. J Endocrinol 1997;153(2):199-205.
42. Zierold C, Mings JA, Prahl JM, Reinholz GG, DeLuca HF. Protein synthesis is required for optimal induction of 25-hydroxyvitamin D(3)-24-hydroxylase, osteocalcin, and osteopontin mRNA by 1,25-dihydroxyvitamin D(3). Arch Biochem Biophys 2002; 404(1):18-24.